

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

The significance of CYP1A2 genotype on caffeine
metabolism and exercise performance

A thesis presented in partial fulfilment of the requirements
for
the degree of

Master of Science

in

Human Nutrition

at Massey University, Manawatu,
New Zealand

Michelle Clare McGrath
2015

Abstract

Objective: The objective of this study was to investigate whether a single nucleotide polymorphism (C to A transversion at position -163 downstream of the first transcribed nucleotide) in the enzyme that metabolizes caffeine (CYP1A2), would explain the variability seen in caffeine related responses in endurance exercise performance. In a double blind crossover trial, well trained male endurance athletes ($n=11$, mean VO_2 max 69 ± 4 $\text{mL}\cdot\text{kg}^{-1}\cdot\text{min}^{-1}$) ingested either caffeine (5 $\text{mg}\cdot\text{kg}^{-1}$) or a placebo 60 minutes prior to performing a lab based experimental protocol involving a two hour steady state cycle (70% VO_2 max) followed by a 30 minute time trial to measure performance. The rate of caffeine metabolism over seven hours (inclusive of exercise period) was also determined by the HPLC analysis of plasma caffeine and its major metabolites, paraxanthine, theophylline and theobromine. Caffeine metabolism at rest over a similar seven hour period was also determined in the same manner.

Results: Caffeine improved endurance performance by 7.1% ($p=0.037$) compared to a placebo. Caffeine also significantly elevated heart rate during the time trial ($p=0.003$); and RPE ($p=0.010$) and VO_2 ($p=0.047$) during steady state exercise. There was no correlation between caffeine or paraxanthine concentrations at the start of the time trial and subsequent performance and the rate of caffeine metabolism was not significantly different between resting or exercising trials. Furthermore there was no significant interaction between caffeine treatment and CYP1A2 genotype on performance or any other

variables measured. However there was a trend for carriers of the C allele showing faster metabolism than those homozygous A/A ($p=0.097$).

Conclusions: Caffeine is ergogenic during endurance exercise, however individual responses were variable. In this study this variability could not be explained by CYP1A2 genotype. However the small sample size in this study especially when subjects were divided into genotype groups, makes drawing conclusions difficult.

Acknowledgements

Firstly, I would like to acknowledge my supervisors Dr Jasmine Thomson and Associate Professor Steve Stannard. Thank you for your encouragement and support and keeping me on track when things got hard. I appreciate you sharing your diverse knowledge and being available when I needed it.

Thank you to Mrs Shampa De for assistance with genotyping and real time PCR, Mrs Chris Booth for helping when I needed an “extra pair of hands” during my trial days and Dr Carlene Starck for assistance with pharmacokinetic calculations. Your assistance was greatly appreciated.

To my partner Craig, a big thank you to putting up with my being constantly busy over the years. It’s been a long time coming but it is finally over!

To my subjects, thank you for giving up your time and the effort you put in. I know it was hard but you were great!

Lastly a thank you to caffeine for helping me get through many a long night!

Approval for the research was obtained from Massey University Human Ethics Committee (HEC: Southern A Application 11/35) for the experiments described in this thesis.

Table of Contents

Abstract.....	i
Acknowledgements.....	iii
List of Figures	ix
List of Tables.....	xi
Abbreviations	xiii
Chapter 1 Introduction	1
1.1. Caffeine use in sport.....	1
Chapter 2 Literature Review	5
2.1. Caffeine content of various dietary sources.....	5
2.1.1. Café coffee.....	5
2.1.2. Other caffeine-containing beverages.....	7
2.1.3. Caffeine absorption	10
2.1.4. Effect of carbohydrate and breakfast on absorption.....	10
2.1.5. Effect of habitual intake	13
2.1.6. Effect of exercise on caffeine absorption and elimination.....	13
2.1.7. Effect of gender, age, body composition and training status on caffeine pharmacokinetics	15
2.2. Caffeine metabolism	15
2.3. CYP1A2 genotype	18
2.3.1. CYP1A2 (-163C>A).....	18
2.3.2. Differences in the rate of caffeine metabolism in relation to genotype.....	19
2.4. Caffeine mechanisms of action on exercise performance.....	22
2.4.1. Glycogen sparing	22
2.4.2. Peripheral actions of caffeine	25
2.4.3. Sympathetic nervous system stimulation	27
2.4.4. Adenosine and blocking of Adenosine receptors	28
2.4.5. Perceived exertion (RPE).....	31
2.5. Effects of caffeine on endurance performance	33
2.5.1. Effect of caffeine co-ingested with carbohydrate.....	34
2.5.2. Effect of low doses of caffeine.....	36
2.5.3. Effect of divided doses of caffeine.....	37
2.5.4. The effect of coffee vs. anhydrous caffeine on endurance performance.....	38
2.5.5. The effect of caffeine withdrawal on endurance performance ..	40

2.5.6. The effect of caffeine on endurance performance in relation to CYP1A2 genotype.....	41
Chapter 3 Materials and Methods.....	43
3.1. General Design	43
3.2. Recruitment process.....	47
3.3. Subject Characteristics.....	47
3.4. Inclusion criteria.....	48
3.5. Exclusion criteria	48
3.6. Diet and activity before the testing.....	49
3.7. Preliminary testing.....	49
3.8. VO ₂ Max.....	50
3.9. Caffeine	51
3.10. Sample collection and analyses	51
3.10.1. Experimental exercise protocol.....	51
3.10.2. Caffeine intervention at rest.....	56
3.10.3. HPLC quantification of plasma caffeine and metabolite (theobromine, paraxanthine and theophylline) concentrations	56
3.10.4. Genotyping	58
3.10.5. Calculating rate of substrate oxidation.....	60
3.10.6. Statistical analyses	60
Chapter 4 Results.....	62
4.1. CYP1A2 Genotype (rs762551).....	62
4.2. Performance Data	64
4.2.1. Performance during time trial.....	64
4.2.2. Heart rate during time trial	65
4.3. Data during steady state exercise	66
4.3.1. Rating of perceived exertion (RPE).....	66
4.3.2. Heart Rate (HR).....	67
4.3.3. Rate of oxygen consumption (VO ₂).....	68
4.3.4. Respiratory Exchange Ratio (RER)	70
4.3.5. Calculated rates of substrate metabolism	70
4.3.6. Subject perception of caffeine ingestion	71
4.4. Caffeine and metabolites.....	72
4.4.1. Plasma caffeine and caffeine metabolite concentrations	72
4.4.2. Estimated rates of caffeine metabolism	74
Chapter 5 Discussion	77
5.1. Purpose of the study.....	77
5.2. Main Findings	77

5.2.3.	The effect of caffeine on endurance performance	77
5.2.4.	The effect of CYP1A2 polymorphism on exercise performance	79
5.2.5.	Ergogenic potential of caffeine metabolites	80
5.2.6.	The effect of CYP1A2 polymorphism on rate of caffeine metabolism	82
5.3.	Habitual caffeine intake.....	85
5.4.	Effect of caffeine on other physiological parameters	85
5.5.	Limitations and future work	87
5.6.	Conclusions	89
Appendix 1	Recruitment Flyer.....	103
Appendix 2	Participant Consent Form	107
Appendix 3	Participant Health Questionnaire	111
Appendix 4	List of Foods and Drinks to Avoid 48 Hours Prior to Trial....	115
Appendix 5	Two Day Diet Record	119
Appendix 6	24 Hour Physical Activity Record	123
Appendix 7	VO ₂ Max Test Form	129
Appendix 8	Caffeine Certificate of Analysis	133
Appendix 9	Exercise Trial Day Data Form	137
Appendix 10	Macronutrient Content of the Standardised Breakfast.....	141
Appendix 11	RPE Scale.....	145
Appendix 12	DNA Extraction Method.....	149
Appendix 13	Rs762551 CYP1A2 Genotyping Method.....	153

List of Figures

Figure 2.1.	Representation of caffeine content (mg) found in a usual serving size of some common caffeine containing food and drinks.	9
Figure 2.2.	CYP1A2 enzymatic metabolism of caffeine in the liver to produce the three major caffeine metabolites, paraxanthine, theophylline and theobromine.	17
Figure 2.3.	Structure of caffeine and adenosine (2015)	29
Figure 3.1	Diagrammatic representation of exercise trial days. Blood samples are timed from caffeine ingestion.	45
Figure 3.2.	Typical HPLC chromatogram of deproteinised plasma showing caffeine and main metabolites.....	58
Figure 3.3.	Melting peaks for CYP1A2 genotype (rs76251)	60
Figure 4.1.	A visual representation of the different melting peaks showing distinct groupings.	63
Figure 4.2.	Average accumulated energy value (kJ) \pm SD on completion of time trial after ingesting either placebo or caffeine.....	65
Figure 4.3.	Comparing the effect of caffeine on heart rate during the time trial. Values are mean \pm SD.	66
Figure 4.4.	RPE during 120 minutes steady state exercise comparing RPE vs. exercise time for placebo and caffeine dosed subjects. Values are mean \pm SD.	67
Figure 4.5.	Heart rate during 120 minutes steady state exercise.	68
Figure 4.6.	VO ₂ during 120 minutes steady state exercise	69
Figure 4.7.	Oxygen consumption/heart beat during 120 minutes steady state exercise.	69
Figure 4.8.	Respiratory exchange ratio during 120 minutes steady state exercise.	70
Figure 4.9.	Carbohydrate and fat oxidation during 120 minutes steady state exercise	71
Figure 4.10.	The effect of genotype on caffeine concentration over time. Data is from both resting and exercise trials for all subjects.....	73
Figure 4.11.	PX/Caffeine ratio at 7 hours. Data is from both resting and exercise trials for all subjects.....	75

List of Tables

Table 2.1.	The effect breakfast/carbohydrate has on caffeine absorption.	12
Table 3.1.	Number of caffeinated coffee or energy drinks consumed by the subjects per week.....	48
Table 4.1.	Average concentration ($\mu\text{mol.L}^{-1}$) during the exercise trial of caffeine and main metabolites paraxanthine (PX), theobromine (TB) and theophylline (TP)	73
Table 4.2.	Pharmacokinetic parameters for Caffeine–Rest trial.....	76
Table 4.3.	Pharmacokinetic parameters for Caffeine–Ex trial	76

Abbreviations

137X	1,3,7-trimethylxanthine (caffeine)
17U	1,7-dimethyluric acid
17X	1,7-dimethylxanthine (paraxanthine)
1U	1-methyluracil
1X	1-methylxanthine
AFMU	5-acetylamino-6-formylamino-3-methyluracil
AUC	Area Under the Curve
BW	Body Weight
Caffeine-Ex	Exercise trial with Caffeine
Caffeine-Rest	Resting trial with Caffeine
cAMP	cyclic adenosine monophosphate
CNS	Central Nervous System
CYP1A2	Cytochrome P450 1A2
DNA	Deoxyribonucleic Acid
EDL	Extensor digitorum longus muscle
EDTA	Ethylenediaminetetraacetic acid
FFA	Free Fatty Acids
HIT	High Intensity Training
HPLC	High Performance Liquid Chromatography
HR	Heart Rate
NMR	Nuclear Magnetic Resonance
PAH	Polycyclic aromatic hydrocarbons
PCR	Polymerase Chain Reaction
Placebo- Ex	Exercise trial with Placebo
PX	Paraxanthine
RER	Respiratory Exchange Ratio
RPE	Rating of Perceived Exertion
SNP	Single Nucleotide Polymorphism
TB	Theobromine
TFA	Trifluoroacetic Acid
TP	Theophylline

USDA	United States Department of Agriculture
VO_2	Volume of Oxygen
VO_2 max	Maximal Oxygen Uptake
WADA	World Anti-Doping Agency